PRECISION ONCOLOGY DIAGNOSTICS
Redefining Cancer Detection
Cancer diagnostics is entering a new era. Single-marker tests, mutation-only liquid biopsies, and isolated genomic panels are no longer sufficient to fully characterize disease biology. The next standard will be integrated, functional, and reproducible across real-world clinical settings. We are building that standard.
Our oncology medical testing services integrate proteomic, metabolic, and molecular architectures to create multi-dimensional cancer panels across multiple myeloma diagnostics, advanced prostate cancer screening beyond PSA, and multi-cancer early detection programs. By capturing both genetic alterations and downstream functional biology, our assays are structured to improve biological resolution, reduce diagnostic ambiguity, and strengthen clinical decision confidence.
We are not a research lab exploring concepts. We are a CLIA-certified, CAP-accredited diagnostic company operating under regulated quality systems. Our assays are CPT-coded, insurance-covered, and actively deployed in clinical practice. Programs are built from inception with analytical validation, reimbursement feasibility, and scalability in mind.
✓ Multiple Myeloma Monitoring & Disease Stratification
✓ Prostate Cancer Risk Assessment Beyond PSA Alone
✓ Multi-Cancer Detection Panels with Integrated Multi-Omics Architecture
Next-Generation LDT Assays for Precision Cancer Detection
(Explore each panel for clinical details)
Founder-Led Scientific Authority
All oncology panel development is directly supervised by Qing Wang, PhD, founder and scientific lead. Dr. Wang trained under Dr. Bert Vogelstein — widely recognized as the father of cancer liquid biopsy — and has spent his career at the intersection of cancer genomics, proteomics, and early detection science.
This foundation is not symbolic. It defines our scientific rigor. Our panels are built with quantitative discipline, deep biomarker validation, and translational structure designed to withstand clinical scrutiny.
We do not treat diagnostics as exploratory research. We engineer them for clinical permanence.
✓ CLIA-Certified Clinical Laboratory
✓ CAP-Accredited Quality Infrastructure
✓ CPT-Coded & Insurance-Reimbursed Assays
✓ Founder-Led Oncology Panel Oversight
Cancer diagnostics will be won by platforms that combine depth, reproducibility, regulatory alignment, and deployment discipline. We are building the infrastructure that defines that future.